Tagged with EDA

regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…

Turkey Dr. Erdal Bozdoğan, the recently appointed general manager of Takeda Turkey, leverages his 20 years of experience in the pharmaceutical industry and his expertise of emerging markets to document Turkey’s attractiveness for Takeda and how, as a doctor, his patient orientated mindset is “no longer a dream but a reality”,…

UK As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back on the company’s internationalisation path. He further highlights the extremely collaborative approach Takeda engages in with NICE and gives tips…

Portugal RJ Lasek took on his first country lead position in Portugal in 2016 and has successfully reshaped the affiliate to match global operations, forecasting 40 percent growth for 2018. In this interview, he sheds light on how to excel in the challenging pharmaceutical landscape–particularly with reimbursement restrictions and what characterizes…

R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…

India Ashok Battacharya, executive director of the Indian affiliate of Takeda Pharmaceuticals, with 38 years experience in global Ppharmaceutical MNCs, discusses the top-notch reputation that Takeda has among physicians and patients and how the company is working towards making Takeda’s innovative medications available to Indian Patients. Can you give our international…

Ukraine Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company under the conditions of significant changes in the pharmaceutical market and Ukrainian healthcare system.   Nobody can deny that Ukraine…

Singapore The Asia-Pacific region is a vast geographic area, home to almost half of the world’s population and numerous emerging and developed markets with great investment potential for healthcare and life sciences companies. However, the degree of diversity within Asia-Pacific creates formidable challenges for MNCs operating in the region. “APAC is…

Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…

Ireland Shane Ryan, in his first month as Country Lead for Takeda Products Ireland, speaks about his mandate to position Takeda as the leader in IBD and oncology with exciting new product launches, the evolving pharmaceutical and healthcare landscape in Ireland, and the drive to help patients that motivates him every…

Singapore Takeda’s President of Emerging Markets Business Unit, Giles Platford, speaks about his assignments across various global markets, his leadership philosophy, as well as the impressive international growth of the company.   I feel a strong sense of responsibility and obligation working for a company that has potentially life-saving and life-transforming…

Singapore In an interview with Takeda’s President of Emerging Markets Business Unit, Giles Platford portrays a vitalized focus on emerging markets and explains why those countries are positioned as one of three key growth drivers for the company. With Takeda’s recently unveiled Access-to-Medicines (AtM) strategy, he also characterizes the role of…